These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20536348)

  • 1. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
    Yu W; Sun X; Tang H; Tao Y; Dai Z
    Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
    Advani AS; Dressman HK; Quiroz M; Taylor GA; Pendergast AM
    Leuk Res; 2004 Mar; 28(3):285-94. PubMed ID: 14687624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.
    Salgia R; Quackenbush E; Lin J; Souchkova N; Sattler M; Ewaniuk DS; Klucher KM; Daley GQ; Kraeft SK; Sackstein R; Alyea EP; von Andrian UH; Chen LB; Gutierrez-Ramos JC; Pendergast AM; Griffin JD
    Blood; 1999 Dec; 94(12):4233-46. PubMed ID: 10590068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
    Mian AA; Metodieva A; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
    Haematologica; 2012 Feb; 97(2):251-7. PubMed ID: 22058195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/CAS9-mediated knockout of Abi1 inhibits p185
    Faulkner J; Jiang P; Farris D; Walker R; Dai Z
    J Hematol Oncol; 2020 Apr; 13(1):34. PubMed ID: 32276588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of leukaemogenic tyrosine kinases on cell motility is governed by subcellular localisation.
    Pierce A; Lu Y; Hamzah HG; Thompson S; Owen-Lynch PJ; Whetton AD; Spooncer E
    Br J Haematol; 2006 May; 133(3):345-52. PubMed ID: 16643438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr-Abl-induced transformation and leukemogenesis.
    Zuo B; Li M; Liu Y; Li K; Ma S; Cui M; Qin Y; Zhu H; Pan X; Guo J; Dai Z; Yu W
    Leuk Lymphoma; 2015 Jul; 56(7):2170-81. PubMed ID: 25363403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
    Jonuleit T; van der Kuip H; Miething C; Michels H; Hallek M; Duyster J; Aulitzky WE
    Blood; 2000 Sep; 96(5):1933-9. PubMed ID: 10961897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells.
    Aichberger KJ; Mayerhofer M; Vales A; Krauth MT; Gleixner KV; Bilban M; Esterbauer H; Sonneck K; Florian S; Derdak S; Pickl WF; Agis H; Falus A; Sillaber C; Valent P
    Blood; 2006 Nov; 108(10):3538-47. PubMed ID: 16849647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells.
    Tipping AJ; Melo JV
    Leuk Res; 2004 Mar; 28(3):219-20. PubMed ID: 14687613
    [No Abstract]   [Full Text] [Related]  

  • 13. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
    Hickey FB; England K; Cotter TG
    J Leukoc Biol; 2005 Jul; 78(1):289-300. PubMed ID: 15857938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.